Sigma Planning Corp Sells 22,011 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Sigma Planning Corp lessened its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 63.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 12,430 shares of the biotechnology company’s stock after selling 22,011 shares during the period. Sigma Planning Corp’s holdings in REGENXBIO were worth $223,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of RGNX. Harbor Capital Advisors Inc. raised its position in REGENXBIO by 10.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 48,559 shares of the biotechnology company’s stock worth $799,000 after purchasing an additional 4,453 shares during the last quarter. Raymond James & Associates raised its position in shares of REGENXBIO by 405.3% during the 3rd quarter. Raymond James & Associates now owns 100,620 shares of the biotechnology company’s stock valued at $1,656,000 after acquiring an additional 80,706 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of REGENXBIO by 77.1% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 114,962 shares of the biotechnology company’s stock valued at $1,892,000 after acquiring an additional 50,056 shares during the last quarter. Prentiss Smith & Co. Inc. bought a new stake in shares of REGENXBIO during the 3rd quarter valued at $185,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of REGENXBIO by 47.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,540 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 3,379 shares during the last quarter. Institutional investors own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

RGNX has been the subject of several recent research reports. Leerink Partnrs upgraded shares of REGENXBIO from a “market perform” rating to an “outperform” rating in a research report on Wednesday, March 6th. Chardan Capital restated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 7th. Stifel Nicolaus restated a “buy” rating and issued a $40.00 price objective on shares of REGENXBIO in a research report on Friday, April 12th. Robert W. Baird upped their price objective on shares of REGENXBIO from $34.00 to $39.00 and gave the company an “outperform” rating in a research report on Wednesday, March 6th. Finally, SVB Leerink upgraded shares of REGENXBIO from a “market perform” rating to an “outperform” rating and set a $37.00 price objective for the company in a research report on Wednesday, March 6th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.45.

REGENXBIO Stock Up 0.8 %

Shares of NASDAQ RGNX opened at $16.19 on Monday. REGENXBIO Inc. has a 1-year low of $11.83 and a 1-year high of $28.80. The company has a fifty day moving average price of $19.87 and a 200 day moving average price of $17.85.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.16). REGENXBIO had a negative return on equity of 68.18% and a negative net margin of 291.99%. The company had revenue of $22.30 million during the quarter, compared to analyst estimates of $34.01 million. During the same period in the previous year, the company posted ($1.38) earnings per share. REGENXBIO’s revenue for the quarter was down 28.8% on a year-over-year basis. As a group, sell-side analysts forecast that REGENXBIO Inc. will post -3.98 earnings per share for the current fiscal year.

Insider Transactions at REGENXBIO

In related news, insider Steve Pakola sold 12,878 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $28.36, for a total value of $365,220.08. Following the completion of the sale, the insider now directly owns 107,192 shares in the company, valued at approximately $3,039,965.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Steve Pakola sold 12,878 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $28.36, for a total value of $365,220.08. Following the completion of the sale, the insider now directly owns 107,192 shares in the company, valued at approximately $3,039,965.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kenneth T. Mills sold 15,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $18.19, for a total transaction of $272,850.00. Following the completion of the transaction, the chief executive officer now directly owns 408,035 shares in the company, valued at $7,422,156.65. The disclosure for this sale can be found here. Insiders sold a total of 57,878 shares of company stock worth $1,217,370 in the last three months. Insiders own 13.13% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.